Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., ...

Pillar Biosciences, Inc., the leader in Decision Medicine(TM), announced its participation in the 2025 Association for Molecular Pathology (AMP) Annual Meeting in Boston, MA. The company and ...

Pharmacists are integral to oncology care, optimizing treatment plans, managing adverse effects, and supporting precision medicine through collaborative practice agreements.

Biomarker testing helps identify effective targeted therapies and avoid those that are less likely to work in certain ...

In a breakthrough that redefines both speed and clinical potential, a new world record for the fastest human whole genome ...

Scientists at Virginia Tech's Fralin Biomedical Research Institute at VTC and their collaborators are exploring emerging trends in cancer immunotherapy with back-to-back review articles published in ...

QIAGEN N.V. today announced the launch of the EZ2 DNA Investigator Sep&Prep Kit, a fully automated solution for processing sexual assault samples, at the upcoming International Symposium on Human ...

In this interview, we explore how single-cell technologies, automation and strategic partnerships are shaping the future of cancer immunotherapy.

DNA sequencing alone misses many disease dynamics. Researchers are turning to epigenomic profiling, especially the biomarker ...

Cleared by the FDA in 2024, the test gained real-world traction in 2025 when it was incorporated into a new global framework ...